Status:
NOT_YET_RECRUITING
Methotrexate Iontophoresis Versus Methotrexate 1% Gel on Depigmentation in Vitiligo Patients
Lead Sponsor:
Pharos University in Alexandria
Conditions:
Vitiligo - Evaluation of Methotrexate Iontophoresis and Topical Methotrexate Gel as Localized Treatment Approache
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
Vitiligo is a common autoimmune depigmenting disorder characterized by selective destruction of melanocytes. Methotrexate (MTX) has shown potential in stabilizing disease activity and promoting repigm...
Detailed Description
Vitiligo is an autoimmune depigmenting disorder characterized by melanocyte destruction. Methotrexate (MTX) has shown potential in modulating autoimmune activity and promoting repigmentation, but syst...
Eligibility Criteria
Inclusion
- Clinically diagnosed vitiligo confirmed by a dermatologist.
- Stable vitiligo for at least 6 months (no new lesions or progression).
- Age between 18 and 60 years.
- Both male and female patients.
- Presence of localized or segmental vitiligo suitable for topical treatment.
- Willingness to avoid other vitiligo treatments (e.g., phototherapy, corticosteroids) during the study period.
- Able and willing to provide written informed consent and comply with study procedures -
Exclusion
- History of systemic or topical methotrexate use within the past 3 months.
- Unstable or rapidly progressive vitiligo during the last 6 months.
- Presence of other autoimmune or dermatologic disorders that could interfere with study evaluation (e.g., psoriasis, eczema, lupus).
- Known hypersensitivity or allergy to methotrexate or any gel/iontophoresis components.
- Hepatic, renal, or hematologic impairment (abnormal liver function or renal profile).
- Pregnant or breastfeeding women, or those planning pregnancy during the study period.
- Use of phototherapy, corticosteroids, or immunosuppressive therapy within the last 3 months.
- Metal implants or pacemakers, which may contraindicate iontophoresis
- \-
Key Trial Info
Start Date :
November 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 10 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07208890
Start Date
November 10 2025
End Date
March 10 2026
Last Update
October 6 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.